Keira Driansky

Keira is an experienced Life-Science leader with a passion for applying cutting edge science to improve global health. As President of North America for Ipsen, Keira leads the company’s US and Canadian organizations. She is responsible for the Oncology, Rare Disease and Neuroscience Business Units and oversees functions across the enterprise. Keira also serves as a member of Ipsen’s Executive Leadership Team, the Portfolio Committee and Deal Review Board. Prior to joining Ipsen, Keira spent 13 years at AstraZeneca leading teams across the United States, Europe and global functions. She served as Country President for Belgium and Luxembourg, overseeing 14 launches across various therapeutic areas. Previously, she served as VP, Global Commercial Head for Tagrisso across more than 90 countries. A former science researcher, Keira brings broad experience from across the healthcare industry, from commercial leadership to healthcare investing and business development. Keira currently serves on the Board of Directors of the Association of Marshall Scholars, the Beauvoir School, and Life Science Cares Boston. She has previously served as a Board Member the Yale Science & Engineering Association, the AstraZeneca Foundation, Alexion Belgium, and Pharma.be. Keira received her MBA from Harvard Business School and an MPhil in Bioscience Enterprise from the University of Cambridge. Keira also conducted breast cancer epidemiology research at the University of Oxford as a Marshall Scholar and conducted biochemistry research at Yale under a Howard Hughes Medical Fellowship. Keira graduated summa cum laude from Yale College, receiving a B.S. in Applied Mathematics with concentrations in Molecular Biochemistry & Biophysics and Economics.